FindTrial
Sign In

Assessment of Endothelial VAsomotricity after treatment by Nicotinic Acid in Patients presenting a recent Acute Coronary Syndrome - EVAN ACS

Assessment of Endothelial VAsomotricity after treatment by Nicotinic Acid in Patients presenting a recent Acute Coronary Syndrome - EVAN ACS

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2006-005950-57-FR
Enrollment
Unknown
Registered
2007-02-12
Start date
2007-03-23
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute coronary syndrome under 7 days

Interventions

Trade Name: niaspan Pharmaceutical Form: Tablet Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use

Sponsors

French Society of Cardiology
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - acute coronaty syndrome of less than 7 day - age between 18- 75 years - HDLc =65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: - History of Myopathy - familial hypercholesterolemia - renal failure - hepatic failure - LDL< 0.7 g/l - hypothyroidy - coronary artery bypass

Design outcomes

Primary

MeasureTime frame
Main Objective: evaluation of effect of niaspan compared to placebo on endothelial vasodilatation measured on humeral artery ;Secondary Objective: - effect of niaspan on HDL c and apo A / Apo B levels and its action on flow mediated dilatation - measurement of CRP, Cytokines (TNF alpha, Il1, IL6, IL10, IL12, IL18) ;Primary end point(s): - variation of HDL levels - variation of diameter of humeral artery using echography—

Countries

France

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026